Second, regarding PIK3CA mutation, Ogino et al. reported that PIK3CA mutations were associated with shorter cancer specific survival in patients with KRAS wild-type tumors in a series of stage I–III colorectal cancers [21]. This evidence concerns the gene KRAS and colorectal cancer.